These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32428613)

  • 1. Management of immune checkpoint inhibitor-induced bullous pemphigoid.
    Apalla Z; Lallas A; Delli F; Lazaridou E; Papalampou S; Apostolidou S; Gerochristou M; Rigopoulos D; Stratigos A; Nikolaou V
    J Am Acad Dermatol; 2021 Feb; 84(2):540-543. PubMed ID: 32428613
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis of pemphigoid nodularis with serological assay.
    Zhiliang L; Peiying J; Suying F
    G Ital Dermatol Venereol; 2016 Feb; 151(1):116-7. PubMed ID: 26924030
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of atypical bullous pemphigoid with generalized pruritus and eczema as the prodrome for 10 years.
    Ikeda T; Okamoto K; Furukawa F
    J Dermatol; 2012 Aug; 39(8):720-1. PubMed ID: 22011062
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
    Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
    J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.
    Shi CR; Otto TS; Thompson LL; Chang MS; Reynolds KL; Chen ST
    Eur J Cancer; 2021 Dec; 159():34-37. PubMed ID: 34731747
    [No Abstract]   [Full Text] [Related]  

  • 6. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Transforming Growth Factor Beta and Immune Checkpoints Induces a Distinctively Distributed, Severe Bullous Pemphigoid.
    Choi SH; Chung KB; Kim DY
    Acta Derm Venereol; 2021 Jun; 101(6):adv00489. PubMed ID: 34159393
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study.
    Molina GE; Reynolds KL; Chen ST
    Br J Dermatol; 2020 Dec; 183(6):1126-1128. PubMed ID: 32531797
    [No Abstract]   [Full Text] [Related]  

  • 10. Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
    Kramer N; Müller G; Zierold S; Röckel M; Fröhlich W; Schefzyk M; Kumbrink J; Hassel JC; Berking C; Ziemer M; Nashan D; French LE; Vera J; Kerl-French KE; Gutzmer R; Heinzerling L
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):e722-e728. PubMed ID: 38400651
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of erythematous skin lesions in bullous pemphigoid associated with atopic dermatitis.
    Kamiya K; Aoyama Y; Nishio E; Horio A; Tokura Y
    J Dermatol; 2016 Sep; 43(9):1102-3. PubMed ID: 26946485
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-induced bullous pemphigoid: Towards a new class of drug-drug interaction?
    Pujalte-Martin M; Rocher F; Cardot-Leccia N; Giacchero D; Borchiellini D
    Eur J Cancer; 2020 Oct; 138():122-124. PubMed ID: 32877796
    [No Abstract]   [Full Text] [Related]  

  • 13. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and topical corticosteroids in bullous pemphigoid.
    Ardern-Jones MR; Venning VA; Wojnarowska F
    N Engl J Med; 2002 Jul; 347(2):143-5; author reply 143-5. PubMed ID: 12110747
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-bullous lesions as the first manifestation of bullous pemphigoid: A retrospective analysis of 181 cases.
    Zhang Y; Luo Y; Han Y; Tian R; Li W; Yao X
    J Dermatol; 2017 Jul; 44(7):742-746. PubMed ID: 28256743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Use of Rituximab and Intravenous Gamma Globulin to Treat Checkpoint Inhibitor- Induced Severe Lichen Planus Pemphigoides.
    Brennan M; Baldissano M; King L; Gaspari AA
    Skinmed; 2020; 18(4):246-249. PubMed ID: 33050991
    [No Abstract]   [Full Text] [Related]  

  • 17. The safety of topical vs. oral steroids in bullous pemphigoid: considerations for retrospective analyses.
    Amber KT; Feldman RJ
    Br J Dermatol; 2024 Sep; 191(4):479-480. PubMed ID: 38912800
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of bullous pemphigoid ınduced by vildagliptin.
    Keseroglu HO; Taş-Aygar G; Gönül M; Gököz O; Ersoy-Evans S
    Cutan Ocul Toxicol; 2017 Jun; 36(2):201-202. PubMed ID: 27460861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
    Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
    J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.
    Said JT; Talia J; Wei E; Mostaghimi A; Semenov Y; Giobbie-Hurder A; Chen ST; LeBoeuf NR
    J Am Acad Dermatol; 2023 Mar; 88(3):670-671. PubMed ID: 35779636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.